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Abstract 
Background: We aimed to investigate the efficacy of high-dose vitamin C, 
melatonin, and zinc in patients with severe Covid-19.  
Materials and Methods: Twenty-one adult patients were randomized 1:1 to 
standard care alone or standard care plus IV vitamin C (2 g, q6hr), oral 
melatonin (6 mg, q6hr), and oral zinc sulfate (50 mg, q6hr) for 10 days. 
Patients were monitored for changes in hypoxemia and inflammatory markers.  
Results: Both treatment modalities were effective to improve PaO2/FiO2 
and oxygen saturation. However, there were no significant differences 
between the 2 study groups (P>0.05). There were reductions in CRP, ESR, 
and LDH levels in both study groups, although were not significant. No 
significant difference was noted in the length of ICU stay between the 2 study 
groups (P=0.3).  
Conclusion: Our study suggests that the addition of vitamin C, melatonin, 
and zinc to standard care is not associated with considerable improvement in 
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Coronavirus disease 2019 (Covid-19) a global 
pandemic is defined as an illness caused by a novel 
coronavirus now called severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) (1, 2). At 
present, there is no data in the literature about the 
combination of vitamin C, melatonin, and zinc for 
treating Covid-19 (3, 4). This was our purpose. We 
hypothesized that combined administration of high-
dose vitamin C, melatonin, and zinc can improve 
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Methods 
Study design: This randomized, single-center, active-
controlled, open-label, parallel-group, compassionate 
use study was performed in Kowsar Hospital, Semnan, 
Iran. The Institutional Ethics Committee, Semnan 
University of Medical Sciences approved the study 
coded IR.SEMUMS.REC.1399.005 while the study 
was registered in the Iranian Clinical Trial registry 
coded IRCT20151228025732N52. Diagnosis of 
Covid-19 was done using real-time PCR (ABI, USA) 
in a respiratory tract sample. Subjects with a positive 
Covid-19 who aged between 18 and 65 years were 
included. They had confirmed pneumonia, oxygen 
saturation (SaO2) less than 94%, and partial pressure 
of oxygen (PaO2) to the fraction inspired oxygen 
(FiO2) below 200 mmHg. Patients with severe 
infection who admitted to intensive care unit (ICU) 
were randomized 1:1 to standard care alone or standard 
care plus IV vitamin C (2g, q6hr), oral melatonin (6 
mg, q6hr), and oral zinc sulfate (220 mg containing 50 
mg elemental zinc, q6hr) for 10 days (5-7). 
Our standard cares were azithromycin (250 
mg/day), lopinavir/ritonavir (100mg/25mg/day), 
glucocorticoids, and necessary oxygen. Patients did 
not receive either remdesivir or tocilizumab and were 
excluded if they had a history of nephrolithiasis, 
allergy to study drugs, pregnancy, hepatic diseases 
with aminotransferase exceeding 5 times the upper 
limit of the normal range, use of fluvoxamine, sodium 
oxybate and alcohol, history of copper deficiency, and 
renal failure (estimated glomerular filtration rate of 
less than 30 ml/min). Also, the patients were excluded 
from the study for these reasons: safety, loss of follow-
up, and voluntary reluctance. Informed consent forms 
were taken from patients or their legal representatives 
before trial.  
 
Assessment of response: Changes in severity of 
hypoxemia (PaO2/FiO2 ratio) were the primary 
exploratory outcomes. In addition, inflammatory 
markers including lactate dehydrogenase (LDH), 
erythrocyte sedimentation rate (ESR), ferritin, and C-
reactive protein (CRP) were measured at baseline, day 
5, and day 10 after treatment initiation.  
 
Data analysis: This study was a pilot study to define a 
sample size. Data are shown as Mean ± SD. Shapiro-
Wilk was used to test the normality of data. We used 
x2 and Fisher’s exact test to study the associations 
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189 ± 40 
 
90 ± 1 
204.1 ± 31.9 
 
93.3 ± 1 
222.2 ± 65 
 
95.1 ± 2 
178 ± 57 
 
90 ± 3 
211.0 ± 29.3 
 
94.2 ± 1 
230.1 ± 59.1* 
 




LDH (U/L) 665.7 ± 224 774 ± 222.1 788 ± 241.3 667.9 ± 
233.7 
761 ± 219.3 796 ± 231.9 0.9 
ESR (mm/hr) 46.3 ± 28.6 35 ± 22.1 36 ± 24.1* 47.3 ± 28.3 39.1 ± 24.1 37.1 ± 26.8 0.08 
CRP (mg/L) 10.4 ± 5.3 6.1 ± 3.6 4.4 ± 3.1* 10.3 ± 5.1 5.9 ± 3.3 4.8 ± 3.6* 0.06 
Ferritin (ng/mL) 422.3 ± 
187.1 




601.7 ± 228 588.3 ± 235.6 0.2 
WBC count, 109/L 10.7 ± 4.3 9.7 ± 4.3 9.9 ± 4.3 10.9 ± 4.1 10 ± 3.9 9.1 ± 3.3 0.2 
Lymphocyte (%) 18.8 ± 8.4 16.8 ± 9.4 17.1 ± 9 18.8 ± 7.9 16.1 ± 6.9 18.8 ± 9.9 0.1 
Neutrophil/lymphocyte 7.8 ± 6.5 7.5 ± 6.6 7.2 ± 4.8 7.9 ± 6.9 7.9 ± 4.5 8 ± 4.6 0.5 
Data are shown as mean  ±  SD or number (%). Analyzed by Friedman test. fraction inspired oxygen to inspired fraction of oxygen 
ratio (PaO2/FiO2) ratio; SaO2: arterial saturation of oxygen, LDH: lactate dehydrogenase; ESR: erythrocyte sedimentation rate; 
CRP: C-reactive protein. * P < 0.05 vs day 0 (baseline). 
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between variables. Friedman's test was used to study 
mean differences. P < 0.05 was considered as statistical 
significance. Analysis was carried out using SPSS 
software (version 14; SPSS Inc, Chicago, IL, USA). 
 
Results 
Baseline characteristics: No patient was lost to follow 
up and all 20 participants were observed over the 
course of 10 days. The range of age was about 20-65 
years in both groups. The mean age was 59 ± 19 years 
with an excess of males (65 % vs 35 %). No significant 
between-group differences in patients ’characteristics 
were seen at enrollment.  
Efficacy: As shown in Table 1, both treatment 
modalities improved PaO2/FiO2 and SaO2. The 
between-group difference was not statistically 
significant at day 10 (P = 0.1). Furthermore, no 
significant difference was noted in the length of ICU 
stay between the 2 groups (15 ± 3.3 days vs 14.1 ± 4.2 
days, P = 0.3). There were no significant differences in 
deterioration of the disease (30% in the control group 
vs 20 % in the treatment group). After 10 days of 
treatment, 2 individuals (20%) did not respond to 
standard care. The study was stopped before the 
completion of treatment in 1 patient due to 




In this randomized trial, we observed for the first time 
that the addition of high-dose vitamin C, high-dose 
melatonin, and zinc to standard care was not associated 
with considerable improvement in patients with severe 
Covid-19. Overall, improvement was not different 
from that associated with usual care alone. Both 
treatment modalities had equal effects on gas 
exchange, LDH, ESR, CRP, ferritin, and lymphocytes. 
Of note, this was a hypothesis-generating study on 
compassionate use of drugs and confirmatory 
investigations are needed.  
Another study indicated that high-dose vitamin 
C (6g/day) could not improve outcomes in patients 
hospitalized due to severe Covid-19 (8). Another pilot 
study by Zhang showed that treatment with 24 g/day 
vitamins for 7 days had no beneficial effects on the 
clinical status of patients with severe Covid-19 (9). 
Finally, a trial with more than 200 patients admitted to 
the general ward reported no significant benefit for 
vitamin C and zinc. Included patients received daily 8-
gram vitamin C with or without 50 mg of zinc for 10 
days (10).  
Though vitamin C has been used in 
perioperative care (11), taken together, the current 
study did fail to open an avenue for vitamin C and other 
supplementary agents like zinc and melatonin in the 
Covid-19 era. 
The most important limitation of the present 
study was the small sample size. We had no power-




Adding high-dose vitamin C, high-dose melatonin, and 
zinc to standard care is not associated with 
considerable improvement in the clinical status of 
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